Enterprise Value
-48.44M
Cash
212.7M
Avg Qtr Burn
-3.627M
Short % of Float
0.49%
Insider Ownership
36.87%
Institutional Own.
13.01%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Natrunix Details Rheumatoid arthritis, Autoimmune disease | Phase 2 Initiation | |
Natrunix (XB2001) Details Pancreatic cancer, Cancer | Phase 1/2 Data readout | |
Hutrukin Details Brain disease, Ischemic stroke | Phase 1 Data readout | |
Natrunix + trifluridine/tipiracil Details Cancer, Colorectal cancer | Phase 1 Update | |
Bermekimab Details Skin disease/disorder | Failed Discontinued | |
514G3 Details Bacterial infection, Methicillin-resistant staphylococcus aureus | Failed Discontinued | |
Bermekimab Details Skin disease/disorder, Hidradenitis suppurativa | Failed Discontinued |